Accretion Nutraveda Ltd (ANL) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Accretion Nutraveda Ltd on NSE and BSE, with an AI summary of each filing.
Please find enclosed herewith Investor/Analysts Presentation for the Half Year ended on 30th September, 2026
Investor Presentation · 03 Nov 2026, 11:29 pm
Accretion Nutraveda Reports Robust H1 FY27 Performance with Revenue Doubling YoY Accretion Nutraveda Limited reported robust financial results for H1 FY27, with total income from operations surging 109.35% YoY to ₹29.44 crore. EBITDA rose 88.03% YoY to ₹6.26 crore with a 21.27% margin, while PAT increased 98.66% YoY to ₹4.73 crore (16.06% margin), translating to an EPS of ₹6.53. Net worth expanded to ₹40.2 crore as of 30th Sep'26. Growth was driven by broad-based demand across Ayurvedic and nutraceutical segments, supported by CDMO services, brand exports, and ongoing capacity and automation expansions.
Intimation regarding update of corporate Identification Number (CIN) of the Company.
Others (Uncategorized) · 03 Nov 2026, 11:20 pm
Accretion Nutraveda Updates Corporate Identification Number Accretion Nutraveda Limited informed BSE that the Ministry of Corporate Affairs updated its Corporate Identification Number (CIN) from L24290GJ2021PLC121216 to L21003GJ2021PLC121216, effective 3rd Nov'26. As per MCA records, the company maintains an authorized capital of ₹8.00 crore and a paid-up capital of ₹7.24 crore.
Accretion Nutraveda Limited inform the stock exchange regarding press release dated 31st October, 2026
Press Release · 01 Nov 2026, 12:56 am
Accretion Nutraveda Delivers Strong H1 FY27 Performance with Net Profit Doubling YoY Accretion Nutraveda reported strong financial results for the half year ended 30th Sep'26 (H1 FY27), with net revenue surging 109.35% YoY to Rs. 29.44 crore from Rs. 14.06 crore in H1 FY26, driven by higher demand for nutraceutical, ayurvedic, and wellness products. EBITDA rose 88.03% YoY to Rs. 6.26 crore, though EBITDA margin contracted 241 bps to 21.27% due to team expansion and regulatory costs. Net profit jumped 98.66% YoY to Rs. 4.73 crore, supported by operational scale and effective cost management.
Please find enclosed herewith Outcome of the Board Meeting dated 31st October, 2026
Outcome · 01 Nov 2026, 12:45 am
Accretion Nutraveda H1 FY27 Net Profit Surges 98.7% YoY Accretion Nutraveda reported strong H1 FY27 (ended 30th Sep'26) results, with revenue from operations surging 109.4% YoY to ₹2,944.47 lakhs versus ₹1,406.46 lakhs in H1 FY26. Total income reached ₹2,960.26 lakhs. PBT rose 95.5% YoY to ₹569.00 lakhs. Net profit increased 98.7% YoY to ₹472.81 lakhs from ₹238.00 lakhs, driving diluted EPS up to ₹6.53 against ₹4.83 in H1 FY26. Operating cash flow improved to ₹113.82 lakhs. The company fully utilized its ₹2,476.80 lakh IPO proceeds toward machinery automation, new setups, and working capital.
Accretion Nutraveda Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/10/2026 ,inter alia, to consider and approve Please find enclosed herewith ....
Intimation · 31 Oct 2026, 5:30 am
Accretion Nutraveda Schedules Board Meeting for H1 FY27 Results Accretion Nutraveda Limited has scheduled a meeting of its Board of Directors for 31st Oct'26. The board will convene inter-alia to consider and approve the company's unaudited financial results for the half year ended 30th Sep'26.
Please find enclosed herewith intimation w.r.t Amendments to Memorandum of Association
Others (Uncategorized) · 11 Oct 2026, 12:40 am
Accretion Nutraveda Approves Alteration of MOA Object Clause via Postal Ballot Accretion Nutraveda Limited announced that its shareholders approved the alteration of Object Clause III of the Memorandum of Association via Postal Ballot on 9th Oct'26. The amendment substitutes Main Object Clause III(A) and inserts new sub-clauses III(B)(58) to III(B)(69). The expanded mandate covers broad-scale manufacturing, trading, and R&D across pharmaceuticals, nutraceuticals, ayurvedic and wellness products, medical devices, hospitals, diagnostic centers, consumer foods, and integrated backward-forward supply chain operations including contract farming and agricultural cultivation.
Please find enclosed herewith with respect to Board Meeting update
Others (Uncategorized) · 02 Sept 2026, 9:07 pm
Accretion Nutraveda Board Approves MOA Expansion and Higher Borrowing Limits On 1st Sep'26, Accretion Nutraveda's Board approved expanding its Memorandum of Association to include pharmaceuticals, nutraceuticals, medical devices, and healthcare facilities. To support this strategic business expansion, the Board authorized enhancements to corporate borrowing limits and mortgage creation thresholds under Section 180 of the Companies Act. Furthermore, directors approved elevating limits for related-party loans, guarantees, and external investments under Sections 185 and 186. All resolutions remain subject to shareholder approval via postal ballot.
Please Find enclosed herewith with respect to Board Meeting update
Others (Uncategorized) · 01 Sept 2026, 6:13 pm
Accretion Nutraveda Board Approves Business Diversification and Higher Borrowing Limits Accretion Nutraveda's board, on 1st Sep'26, approved altering its Memorandum of Association to diversify business activities. This includes manufacturing and trading in pharmaceuticals, nutraceuticals, medical devices, and operating healthcare facilities like hospitals and diagnostic centres. The board also approved proposals to increase borrowing limits, enhance limits for creating security on company assets, and grant loans, guarantees, and investments beyond prescribed thresholds. These approvals are subject to shareholder consent via a postal ballot.
Please find enclosed herewith intimation of alteration of Memorandum of Association (MOA)
Others (Uncategorized) · 01 Sept 2026, 6:09 pm
Accretion Nutraveda Board Approves Debt Limit Increase and Business Expansion Accretion Nutraveda's board, on 01st Sep'26, approved key proposals subject to shareholder approval via postal ballot. These include increasing the company's borrowing limits and altering the Memorandum of Association to expand its main objects. The expansion covers a broad range of activities including backward integration into agriculture, horticulture, and contract farming, as well as forward integration into operating hospitals, diagnostic centers, and CROs. The board also approved granting loans and investments beyond existing limits to support these new ventures.
Please find enclosed herewith declaration of Voting Result and Scrutinizer Report of 5th Annual General Meeting of the Company
Annual General Meeting · 28 Aug 2026, 2:00 am
Please find enclosed herewith proceedings of 5th Annual General Meeting of the Company held on 27th August, 2026
Annual General Meeting · 28 Aug 2026, 12:06 am
Please find enclosed herewith Letter regarding web link of Annual Report to Shareholders
Annual Report · 06 Aug 2026, 10:48 pm
Please find enclosed herewith Notice of the 5th AGM of the Company.
Annual General Meeting · 05 Aug 2026, 4:39 am
Please find enclosed herewith Annual Report of the Company for Financial Year 2025-26.
Others (Uncategorized) · 05 Aug 2026, 4:35 am
Please find enclosed herewith Global Export Excellence Award at the "Leaders of Navbharat Award & Conclave" organized by Times Now Group.
Others (Uncategorized) · 09 Jul 2026, 7:37 pm
Accretion Nutraveda Wins Global Export Excellence Award Accretion Nutraveda Limited (BSE: 544694) announced on 09th Jul'26 that it has received the "Global Export Excellence Award in Ayurvedic & Nutraceutical Manufacturing." The company was recognized at the "Leaders of Navbharat Awards & Conclave," an event organized by the Times Now Group. This award highlights the company's achievements and strength in the export market for its specialized products.
Accretion Nutraveda Limited has informed the Exchange regarding Press Release dated 15th May, 2026, titled "Company Delivers Robust Performance in H2 FY26 : Revenue up 80.09% YOY and EBITDA ....
Press Release · 16 May 2026, 12:29 am
Accretion Nutraveda Reports Strong FY26 Results with Revenue Up 110% YoY For FY26, Accretion Nutraveda reported Net Revenue of Rs. 33.6 crore, up 110.0% YoY, and PAT of Rs. 5.07 crore, a 102.8% YoY increase. EBITDA grew 87.9% YoY to Rs. 7.01 crore. Full-year margins compressed, with EBITDA margin at 20.85% (down 246 bps) and PAT margin at 15.08% (down 55 bps), impacted by higher input costs and expansion expenses. H2 FY26 revenue was Rs. 19.54 crore (+80.1% YoY) with PAT at Rs. 2.69 crore (+56.4% YoY).
Please find enclosed herewith Intimation with respect to Appointment Internal Auditor of the company.
Change in Auditor · 09 May 2026, 1:24 am
Accretion Nutraveda Board Approves FY26 Results and Key Management Changes Accretion Nutraveda's board approved audited financials for the year ending 31st Mar'26, posting a Profit After Tax of ₹506.83 lakhs, up 102.6% YoY from ₹250.09 lakhs. Key outcomes include the resignations of Independent Directors Arun Dash and Mahipal Singh Chouhan, effective 08th May'26. Concurrently, Chand Rameshbhai Kanabar and Grishma A Shewale were appointed as Additional Non-Executive, Independent Directors for five-year terms. The board also appointed new Secretarial and Internal Auditors for FY27. An unmodified audit opinion was issued.
Please find enclosed herewith intimation with respect to Appointment of Secretarial Auditor of the Company.
Change in Auditor · 09 May 2026, 1:16 am
Accretion Nutraveda Reports FY26 Results and Key Board Changes Accretion Nutraveda's board approved audited financial results for the year ended 31st Mar'26, posting a Profit After Tax of ₹506.83 lakh versus ₹250.09 lakh YoY. Revenue from operations stood at ₹3,360.31 lakh. The board announced the resignations of Independent Directors Arun Dash and Mahipal Singh Chouhan, and the appointments of Chand Kanabar and Grishma Shewale as Additional Independent Directors, each for a five-year term effective 08th May'26. Additionally, UMT & Co. was appointed as Internal Auditor and Sakhiya & Co. was re-appointed as Secretarial Auditor for FY27.
Please find enclosed herewith Appointment of Ms. Grishma A Shewale as an Additional Non - Executive Independent Director of the Company.
Change in Management · 09 May 2026, 1:11 am
Accretion Nutraveda Board Changes; FY26 PAT Doubles YoY Accretion Nutraveda's board approved FY26 audited financials on 08 May'26, reporting a 102.6% YoY increase in Profit After Tax to ₹506.83 lakhs from ₹250.09 lakhs. Revenue grew 110% YoY to ₹3,360.31 lakhs. The board appointed Mr. Chand Kanabar and Ms. Grishma Shewale as Additional Independent Directors for five years. Concurrently, Mr. Arun Dash and Mr. Mahipal Singh Chouhan resigned as Independent Directors. Additionally, M/s. UMT & Co. were appointed as Internal Auditors for FY 2026-27.
Please find enclosed herewith Appointment of Mr. Chand Rameshbhai Kanabar as an Additional Non- Executive Independent Director of the Company.
Change in Management · 09 May 2026, 1:06 am
Accretion Nutraveda Reports FY26 Results and Major Board Changes Accretion Nutraveda's board approved audited financials for the year ended 31st Mar'26, posting a Profit After Tax of ₹506.83 lakhs, up 102.5% YoY. Two Non-Executive Independent Directors, Mr. Arun Dash and Mr. Mahipal Singh Chouhan, resigned effective 08th May'26. Concurrently, Mr. Chand Rameshbhai Kanabar and Ms. Grishma A Shewale were appointed as Additional Non-Executive Independent Directors for five-year terms. The board also re-appointed M/s. Sakhiya & Co. as Secretarial Auditors and appointed M/s. U M T & Co. as Internal Auditors for FY27.
Please find enclosed herewith resignation of Mr. Mahipal singh chouhan as non-Executive Independent Director of the Company.
Change in Management · 09 May 2026, 12:39 am
Accretion Nutraveda Board Approves FY26 Results and Announces Director Resignations, Appointments Accretion Nutraveda's board approved audited financials for the year ended 31st Mar'26, posting a Profit After Tax of ₹506.83 lakhs, up 102.6% YoY from ₹250.09 lakhs. Revenue from operations grew 110.0% YoY to ₹3360.31 lakhs. The board noted the resignations of Independent Directors Arun Dash and Mahipal Singh Chouhan, effective 08th May'26. Concurrently, Chand Kanabar and Grishma Shewale were appointed as Additional Non-Executive Independent Directors for five-year terms, subject to shareholder approval. Auditors issued an unmodified opinion on the results.
Please Find Enclosed herewith Resignation of Mr. Arun Dash as Non - Executive Independent Director
Change in Management · 09 May 2026, 12:31 am
Accretion Nutraveda Reports Board Changes and Approves FY26 Audited Financials Accretion Nutraveda’s board on 8th May'26 approved audited results for the year ended 31st Mar'26, posting a Profit After Tax of ₹506.83 lakhs, up 102.6% YoY. The board also noted the resignations of Independent Directors Arun Dash and Mahipal Singh Chouhan. Concurrently, Chand Rameshbhai Kanabar and Grishma A Shewale were appointed as Additional Independent Directors for five-year terms. The board appointed U M T & Co. as Internal Auditor and re-appointed Sakhiya & Co. as Secretarial Auditor for FY 2026-27.
Please find enclosed herewith Outcome of Board Meeting dated 08th May, 2026
Outcome · 09 May 2026, 12:23 am
Accretion Nutraveda Limited - Financial Result for the Quarter ended 31st Mar'26 (Standalone, INR Lakhs) ■ Revenue: 1954 (+80.1% YoY | +38.9% QoQ) ■ EBITDA: 356 (+38.5% YoY | +7.0% QoQ) ■ EBITDA Margin (%): 18.2 (-549 bps YoY | -543 bps QoQ) ■ PAT: 269 (+56.1% YoY | +13.0% QoQ) ■ EPS (INR): 4.53 (-3.6% YoY | -6.2% QoQ)
Accretion Nutraveda Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/05/2026 ,inter alia, to consider and approve Audited Financial Result ....
Intimation · 08 May 2026, 5:30 am
Accretion Nutraveda Board Meeting to Approve FY26 Results on 08th May Accretion Nutraveda Limited (BSE: 544694) has scheduled a Board of Directors meeting on 08th May'26. The primary agenda is to consider and approve the audited financial results for the full financial year ending on 31st Mar'26. This intimation was made to the BSE in compliance with SEBI's listing regulations. The outcome of the meeting will be critical for assessing the company's annual financial performance.
Please find enclosed herewith clarification Letter on price movement
Others (Uncategorized) · 30 Apr 2026, 6:31 pm
Accretion Nutraveda Attributes Stock Price Movement to Market Forces Accretion Nutraveda Limited, in a clarification to the BSE dated 30th Apr'26, stated it has no undisclosed price-sensitive information to report. The company confirmed compliance with SEBI's disclosure requirements. Management attributed the recent significant price movement in its securities as purely market-driven, emphasizing that the company is not involved in or responsible for the fluctuations. The response follows a query from the exchange regarding the stock's price volatility.